Loureirin B

产品说明书

Print
Chemical Structure| 119425-90-0 同义名 : LB; LrB
CAS号 : 119425-90-0
货号 : A472152
分子式 : C18H20O5
纯度 : 99%+
分子量 : 316.35
MDL号 : MFCD07781421
存储条件：

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
靶点

  • Calcium Channel

  • Calcium Channel

  • JNK

  • JNK
描述 Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM. Loureirin B (1, 0.1, and 0.01 µM) increases insulin secretion in Ins-1 cells. Loureirin B (0.01 µM) almost causes no toxicity on cells. Loureirin B improves the level of expressions of MafA and Pdx-1 and ATP level. Loureirin B inhibits the KATP current but increases the [Ca2+]i level in Ins-1 cells[1]. Loureirin B directly inhibited STIM1/Orai1 channel in a dose-dependent manner. Loureirin B inhibits Ca2+ influx and IL-2 secretion in Jurkat T cells by inhibiting both KV1.3 and STIM1/Orai1 channels[2]. Loureirin B inhibits the expression of Col1 and FN, as well as the TGF-β1-mediated up regulation of p-JNK. Loureirin B also inhibits the up regulation of p-ERK that is induced by TGF-β1. Moreover, Loureirin B inhibits the contraction of TGF-β1-stimulated fibroblasts through the down regulation of p-ERK and p-JNK. However, Loureirin B does not suppress the up regulation of p-p38 that is induced by TGF-β1[3]. LrB (Loureirin B) represses osteoclastogenesis, bone resorption, F-actin belts formation, osteoclast specific gene expressions, ROS activity and calcium oscillations through preventing NFATc1 translocation and expression as well as affecting MAPK-NFAT signaling pathways in vitro. In vivo, LrB prevents OVX-induced osteoporosis and preserves bone volume by repressing osteoclast activity and function[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.16mL

0.63mL

0.32mL

15.81mL

3.16mL

1.58mL

31.61mL

6.32mL

3.16mL
参考文献

[1]Sha Y, Zhang Y, Cao J, Qian K, Niu B, Chen Q. Loureirin B promotes insulin secretion through inhibition of KATP channel and influx of intracellular calcium. J Cell Biochem. 2018 Feb;119(2):2012-2021

[2]Shi S, Zhao Q, Ke C, Long S, Zhang F, Zhang X, Li Y, Liu X, Hu H, Yin S. Loureirin B Exerts its Immunosuppressive Effects by Inhibiting STIM1/Orai1 and KV1.3 Channels. Front Pharmacol. 2021 Jun 25;12:685092

[3]He T, Bai X, Yang L, Fan L, Li Y, Su L, Gao J, Han S, Hu D. Loureirin B Inhibits Hypertrophic Scar Formation via Inhibition of the TGF-β1-ERK/JNK Pathway. Cell Physiol Biochem. 2015;37(2):666-76

[4]Liu Y, Wang C, Wang G, Sun Y, Deng Z, Chen L, Chen K, Tickner J, Kenny J, Song D, Zhang Q, Wang H, Chen Z, Zhou C, He W, Xu J. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics. 2019 Jul 3;9(16):4648-4662